CN Patent

CN104606133A — 鲁拉西酮口服混悬液及其制备方法

Assigned to BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co Ltd · Expires 2015-05-13 · 11y expired

What this patent protects

本发明公开了一种鲁拉西酮口服混悬液及其制备方法。所述口服混悬液是一种含有鲁拉西酮或其盐、助悬剂、润湿剂、pH调节剂、防腐剂、甜味剂及矫味剂的药物组合物，其中鲁拉西酮或其盐的粒径范围为0.1~20μm。本发明制备成的口服混悬液具有质量稳定、口感良好、便于分剂量的特点，利于精神分裂症患者所接受，制备方法简单，适合于工业化生产。

USPTO Abstract

本发明公开了一种鲁拉西酮口服混悬液及其制备方法。所述口服混悬液是一种含有鲁拉西酮或其盐、助悬剂、润湿剂、pH调节剂、防腐剂、甜味剂及矫味剂的药物组合物，其中鲁拉西酮或其盐的粒径范围为0.1~20μm。本发明制备成的口服混悬液具有质量稳定、口感良好、便于分剂量的特点，利于精神分裂症患者所接受，制备方法简单，适合于工业化生产。

Drugs covered by this patent

lurasidone-hydrochloride (LURASIDONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN104606133A
Jurisdiction: CN
Classification: —
Expires: 2015-05-13
Drug substance claim: No
Drug product claim: No
Assignee: BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.